Rounds / iCUREX
I
iCUREX raises ¥140M (Series A first close)
Chitosan hydrogel wound dressing (Kitosura CX), a Class III medical device launched in September 2026.
- Company
- iCUREX
- Reported
- 22 Oct 2026 · that week's brief
- Stage
- Series A first close · 「シリーズA 1stクローズ」 · A
- Amount
- ¥140M1 · as announced: 「総額1億4,000万円（シリーズA 1stクローズ：優先株式1億円＋日本政策金融公庫からの融資4,000万円）」
- Breakdown
- Equity ¥100M · Debt ¥40M
- Registry
- Not checked against the registry yet
- Notes
- Kagoshima. Series A first close: 1億円 of preferred shares from NCB Venture Capital, Green Core and INDEP, plus a 4,000万円 Japan Finance Corporation loan (total 1.4億円). Kitosura CX was approved on 1 May 2026, covered by insurance in July and launched in September.
- Investors
- NCB Venture CapitalGreen CoreINDEP
- Lenders
- Japan Finance Corporation (loans; not counted as equity)
- Sector
- HealthcareDeep tech
- Source
- Release (PR TIMES (company release); no announcement found on the company's own site yet)
1 ≈ ~$0.9M at the ECB reference rate on 2026-10-22 (¥1 = $0.00633). Yen is the figure of record. Methodology
Get the weekly brief
Every Japanese funding round worth knowing, in one English email. Free. Subscribe on Substack →
Every Japanese funding round worth knowing, in one English email. Free. Subscribe on Substack →